These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 21172012)
41. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013. Bouvy JC; Blake K; Slattery J; De Bruin ML; Arlett P; Kurz X Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1442-1450. PubMed ID: 28345151 [TBL] [Abstract][Full Text] [Related]
42. Requirements on efficacy of herbal medicinal products. Claeson P J Ethnopharmacol; 2014 Dec; 158 Pt B():463-6. PubMed ID: 25043782 [TBL] [Abstract][Full Text] [Related]
43. Extension of Indication for Authorised Oncology Products in the European Union: A Joint Effort of Multiple Stakeholders. Mulder J; Verjans R; Verbaanderd C; Pean E; Weemers J; Leufkens HGM; Pignatti F; de Boer A; Voest EE; Stoyanova-Beninska VV; Pasmooij AMG Front Med (Lausanne); 2021; 8():790782. PubMed ID: 34957158 [TBL] [Abstract][Full Text] [Related]
44. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lopez AD; Mathers CD; Ezzati M; Jamison DT; Murray CJ Lancet; 2006 May; 367(9524):1747-57. PubMed ID: 16731270 [TBL] [Abstract][Full Text] [Related]
45. The Difference between Approval Processes for Medicinal Products and Medical Devices in Europe. Marshall J; Morrill K; Gobbe M; Blanchard L Ophthalmologica; 2021; 244(5):368-378. PubMed ID: 34062546 [TBL] [Abstract][Full Text] [Related]
46. New drugs: evidence relating to their therapeutic value after introduction to the market. Ujeyl M; Schlegel C; Walter S; Gundert-Remy U Dtsch Arztebl Int; 2012 Feb; 109(7):117-23. PubMed ID: 22427788 [TBL] [Abstract][Full Text] [Related]
47. [Review of the development in European Legislation on the harmonisation of the laws for medicinal products]. Lehmann B Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):713-21. PubMed ID: 18584107 [TBL] [Abstract][Full Text] [Related]
48. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Murray CJ; Lopez AD Lancet; 1997 May; 349(9064):1498-504. PubMed ID: 9167458 [TBL] [Abstract][Full Text] [Related]
49. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective. Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215 [TBL] [Abstract][Full Text] [Related]
50. Similar biological medicinal products containing recombinant human growth hormone: European regulation. Pavlovic M; Girardin E; Kapetanovic L; Ho K; Trouvin JH Horm Res; 2008; 69(1):14-21. PubMed ID: 18059081 [TBL] [Abstract][Full Text] [Related]
51. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority. Tomić S; Sucić AF; Martinac AI Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190 [TBL] [Abstract][Full Text] [Related]
52. The European hospital exemption clause-new option for gene therapy? Buchholz CJ; Sanzenbacher R; Schüle S Hum Gene Ther; 2012 Jan; 23(1):7-12. PubMed ID: 22247961 [TBL] [Abstract][Full Text] [Related]
53. Reflections on Decisions Made on the Well-Established Use of Medicinal Products by EU Regulators and the ECJ. Borg JJ; Laslop A; Pani L; Maciulaitis R; Melchiorri D Sci Pharm; 2014; 82(3):541-54. PubMed ID: 25853067 [TBL] [Abstract][Full Text] [Related]
54. Quality Issues Identified During the Evaluation of Biosimilars by the European Medicines Agency's Committee for Medicinal Products for Human Use. Cilia M; Ruiz S; Richardson P; Salmonson T; Serracino-Inglott A; Wirth F; Borg JJ AAPS PharmSciTech; 2018 Feb; 19(2):489-511. PubMed ID: 29027130 [TBL] [Abstract][Full Text] [Related]
55. Failures to further developing orphan medicinal products after designation granted in Europe: an analysis of marketing authorisation failures and abandoned drugs. Giannuzzi V; Landi A; Bosone E; Giannuzzi F; Nicotri S; Torrent-Farnell J; Bonifazi F; Felisi M; Bonifazi D; Ceci A BMJ Open; 2017 Sep; 7(9):e017358. PubMed ID: 28893754 [TBL] [Abstract][Full Text] [Related]
56. The European Medicines Agency review of ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab: summary of the scientific assessment of the European medicines agency committee for medicinal products for human use. Gravanis I; Ersbøll J; Skovlund E; Abadie E; Marty M; Pignatti F Oncologist; 2010; 15(12):1335-43. PubMed ID: 21156732 [TBL] [Abstract][Full Text] [Related]
57. Three years of paediatric regulation in the European Union. Olski TM; Lampus SF; Gherarducci G; Saint Raymond A Eur J Clin Pharmacol; 2011 Mar; 67(3):245-52. PubMed ID: 21286912 [TBL] [Abstract][Full Text] [Related]
58. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance. Borg JJ; Aislaitner G; Pirozynski M; Mifsud S Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243 [TBL] [Abstract][Full Text] [Related]
59. Evolution of European Union legislation of herbal medicinal products and its transposition to national legislation in 1965-2007: case Finland. Koski SM; Laitinen-Parkkonen P; Airaksinen M Int J Health Plann Manage; 2015; 30(3):260-75. PubMed ID: 24375722 [TBL] [Abstract][Full Text] [Related]